| Identification | Back Directory | [Name]
IRALUKAST | [CAS]
151581-24-7 | [Synonyms]
Iralukast [inn]
Unii-L1E28E0J8f
Iralukast (CGP 45715A)
7-[(2S,3E,5Z)-10-(4-Acetyl-3-Hydroxy-2-Propylphenoxy)-1-Hydroxy-1-[3-(Trifluoromethyl)Phenyl]Deca-3,5-Dien-2-Yl]Sulfanyl-4-Oxochromene-2-Carboxylic Acid
4H-1-Benzopyran-2-carboxylic acid, 7-[[(1S,2E,4Z)-9-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-[(R)-hydroxy[3-(trifluoromethyl)phenyl]methyl]-2,4-nonadien-1-yl]thio]-4-oxo- | [Molecular Formula]
C38H37F3O8S | [MDL Number]
MFCD00864639 | [MOL File]
151581-24-7.mol | [Molecular Weight]
710.76 |
| Hazard Information | Back Directory | [Uses]
Iralukast is a cysteinyl-leukotriene antagonist (CysLT) with a pKi of 7.8 for CysLT1. | [IC 50]
CysLT1: 7.8 (pKi) | [References]
[1] Magnus B?ck, et al. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br J Pharmacol. 2014 Aug; 171(15): 3551–3574. DOI:10.1111/bph.12665
[2] Valérie Capra, et al. Pharmacological characterization of the cysteinyl-leukotrieneantagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro.Br J Pharmacol. 1998 Feb; 123(3): 590–598. DOI:10.1038/sj.bjp.0701636 |
|
|